This is Weave
Weave is re-shaping drug development with AI, evolving the way therapeutic knowledge is maintained, applied, and communicated.
Meet the Co-founders

Brandon Rice
Chief Executive Officer

Ari Caroline
Chief Strategy Officer
At Weave, our customers set the standard for regulatory knowledge management.
Our AI-native platform supports the entire regulatory knowledge lifecycle, from initial planning and content reuse through authoring, review, submission, and post-submission response.
The stakes in this work are exceptionally high: patients’ lives and well-being on one hand, the billions of dollars required to bring a drug to market on the other. We built Weave to equip human experts with the AI tools they need to meet that scrutiny.
Scientists, engineers, and regulatory experts founded Weave, with leading investors and organizations across the life sciences placing their trust in it. Together, we’re helping teams move faster, work smarter, and focus on the science that matters most.
Our Strategic Advisory Board

Russ Altman, M.D., Ph.D.
Stanford University

Tala Fakhouri, Ph.D., M.P.H.
Parexel

Stewart Hen
Serrado Capital

Sean Khozin, M.D., M.P.H.
CEO Roundtable on Cancer

Chris Lee, M.P.H.
Gilead Sciences

Vada Perkins, Ph.D.
Boehringer Ingelheim

Andrew S. Robertson, Ph.D., JD
Denali Therapeutics
Our investors
From Seed to Scale
-
2024
Seed Funding Round
-
2024
Submission Builder Launched
-
2025
Series A Funding
-
2025
HAQ Manager Launched
-
2026
Announced Collaboration with Takeda